The reason behind Pfizer’s paying a lot of money to Merck KGaA

Pfizer is one of the most prominent names in the health care sector that is working for a disease free, healthier and safer world. The sole business of the company is to produce and sell medicines globally. The company came into existence in New York City in the year 1849 by Charles Pfizer and Charles Earnest. PFE is apopular name in the healthcare sector and they have come up with many products that have revolutionized the paradigms of healthcare.  The company is now focusing on buying back stocks which is now their major aim.

However, despite of failing many times in various attempts to sign AstraZeneca, the company switched its attention and signed a block buster deal with Merck KGaA in previous months. This decision left analysts and the board of AstraZeneca inshock as they were expecting that Pfizer will be coming back with another bid to lure the company. According to the deal between Pfizer and Merck KGaA, Pfizer will make an upfront payment of $850 million, with additional payment of $2 billion contingent on regulatory and commercial milestones.

According to Forbes, “The transaction is certainly very significant for Merck KGaA which has found a partner with deep pockets and a quicker entry in the U.S. oncologymarket. From Pfizer’s perspective, this is a massive investment considering the drug’s stage. However, the potential reward could also be big as immuno-oncology market is expected to pick up over the next few years.”

The company is confident in signing a huge cancer deal with Merck KGaA.

AstraZeneca’s boss believes that the future is bright for the company

Pfizer and AstraZeneca are the powerhouses and giants of the pharmaceutical industry.  Both of these companies have dominated the market for many years now in order to make the world a better place to live. However, a few months ago, Pfizer planned to sign a block buster deal to purchase AstraZeneca which the company rejected without having second thoughts. According to the boss of AstraZeneca, he said that “Pfizer ordeal was one of the most testing moments of my career.” This will not be wrong to say as Pfizer gave a very tough time to Pascal Soriot after putting a couple of tempting deals.

The boss of the company and the company itself believes that AstraZeneca is betteroff alone and it was the right decision to reject multiple bids from rivals Pfizer. Moreover, it is believed that the future of pharmaceutical giants AstraZeneca is bright and it can do better business being independent. As Pascal Soriot puts it, “It was a testing period but also a building period for all of us. It really helped the company come together.”

It is sure from the company’s point of view that they are not interested in any other bid from Pfizer and it will be rejected whatsoever. Telegraph reported that “It is not that the AstraZeneca boss feels immune to another approach, though City consensus would suggest he could. It is because the Frenchman has learnt to face the threat of a corporate predator with a philosophical Gallic shrug.”

According to the company officials it was said that Pfizer backed off after the first bid was rejected by AstraZeneca. But Pascal Soriot in his interview with Telegraph said “I tend to be trusting. Back in January when Pfizer said they were withdrawing and no longer interested, I believed it. Then they returned out of the blue.”

AstraZeneca is doing an outstanding business and has been performing well in the market in recent times. Hence, it might be a correct decision to not sign a blockbuster deal with Pfizer.